JP2022512158A5 - - Google Patents

Info

Publication number
JP2022512158A5
JP2022512158A5 JP2021532805A JP2021532805A JP2022512158A5 JP 2022512158 A5 JP2022512158 A5 JP 2022512158A5 JP 2021532805 A JP2021532805 A JP 2021532805A JP 2021532805 A JP2021532805 A JP 2021532805A JP 2022512158 A5 JP2022512158 A5 JP 2022512158A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
administered
talabostat
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021532805A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512158A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/065465 external-priority patent/WO2020123496A1/en
Publication of JP2022512158A publication Critical patent/JP2022512158A/ja
Publication of JP2022512158A5 publication Critical patent/JP2022512158A5/ja
Priority to JP2025113459A priority Critical patent/JP2025156353A/ja
Pending legal-status Critical Current

Links

JP2021532805A 2018-12-10 2019-12-10 免疫調節を使用したがんの治療のための新規アプローチ Pending JP2022512158A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025113459A JP2025156353A (ja) 2018-12-10 2025-07-04 免疫調節を使用したがんの治療のための新規アプローチ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862777352P 2018-12-10 2018-12-10
US62/777,352 2018-12-10
US201962924429P 2019-10-22 2019-10-22
US62/924,429 2019-10-22
PCT/US2019/065465 WO2020123496A1 (en) 2018-12-10 2019-12-10 Novel approach for treatment of cancer using immunomodulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025113459A Division JP2025156353A (ja) 2018-12-10 2025-07-04 免疫調節を使用したがんの治療のための新規アプローチ

Publications (2)

Publication Number Publication Date
JP2022512158A JP2022512158A (ja) 2022-02-02
JP2022512158A5 true JP2022512158A5 (cg-RX-API-DMAC7.html) 2022-12-02

Family

ID=71075816

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021532805A Pending JP2022512158A (ja) 2018-12-10 2019-12-10 免疫調節を使用したがんの治療のための新規アプローチ
JP2025113459A Withdrawn JP2025156353A (ja) 2018-12-10 2025-07-04 免疫調節を使用したがんの治療のための新規アプローチ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025113459A Withdrawn JP2025156353A (ja) 2018-12-10 2025-07-04 免疫調節を使用したがんの治療のための新規アプローチ

Country Status (13)

Country Link
US (1) US20220089733A1 (cg-RX-API-DMAC7.html)
EP (1) EP3893869A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022512158A (cg-RX-API-DMAC7.html)
KR (1) KR20210102259A (cg-RX-API-DMAC7.html)
CN (1) CN113260361A (cg-RX-API-DMAC7.html)
AU (1) AU2019396206A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021011205A2 (cg-RX-API-DMAC7.html)
CA (1) CA3121270A1 (cg-RX-API-DMAC7.html)
IL (1) IL283742A (cg-RX-API-DMAC7.html)
MX (1) MX2021006778A (cg-RX-API-DMAC7.html)
SG (1) SG11202106129RA (cg-RX-API-DMAC7.html)
TW (1) TW202034955A (cg-RX-API-DMAC7.html)
WO (1) WO2020123496A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2991628C (en) 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
EP4099994A4 (en) * 2020-02-07 2024-02-14 OnkosXcel Therapeutics, LLC Treatment regimen for cancer using immunomodulation
WO2023154036A1 (en) * 2022-02-08 2023-08-17 Agios Pharmaceuticals, Inc. Methods for titrating mitapivat

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008033368A2 (en) * 2006-09-12 2008-03-20 Dara Biosciences, Inc. Boroproline compound and cytokine combination therapy
US9295731B2 (en) * 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
US20170369592A1 (en) * 2015-01-09 2017-12-28 Mabimmune Diagostics AG Novel anti-fibroblast activation protein (fap) antibodies and uses derived thereof
CA2991628C (en) * 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. A novel approach for treatment of cancer using immunomodulation
US10954300B2 (en) * 2015-09-28 2021-03-23 The Trustees Of Columbia University In The City Of New York Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
WO2018129497A1 (en) * 2017-01-09 2018-07-12 Bioxcel Therapeutics, Inc. Predictive and diagnostic methods for prostate cancer
CN110914302A (zh) * 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法

Similar Documents

Publication Publication Date Title
JP2019503365A5 (cg-RX-API-DMAC7.html)
FI3849534T3 (fi) Yhdistelmähoidot
JP2017057230A5 (cg-RX-API-DMAC7.html)
EA200800881A1 (ru) Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами
JP2022537551A5 (cg-RX-API-DMAC7.html)
JP2014526503A5 (cg-RX-API-DMAC7.html)
CA2582734A1 (en) Dimeric small molecule potentiators of apoptosis
JP2014515373A5 (cg-RX-API-DMAC7.html)
FI3493812T3 (fi) Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten
JP2018507243A5 (cg-RX-API-DMAC7.html)
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
JP2015522630A5 (cg-RX-API-DMAC7.html)
JP2017506624A5 (cg-RX-API-DMAC7.html)
JP2021535107A5 (cg-RX-API-DMAC7.html)
RU2010107843A (ru) Бупропиона гидробромид и его терапевтические применения
JP2021523220A5 (cg-RX-API-DMAC7.html)
JP2006513184A5 (cg-RX-API-DMAC7.html)
CA2501651A1 (en) Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
JP2020533296A5 (cg-RX-API-DMAC7.html)
JP2021509395A5 (cg-RX-API-DMAC7.html)
JP2016507500A5 (cg-RX-API-DMAC7.html)
MX2024006271A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
MX2024006270A (es) Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2016505050A5 (cg-RX-API-DMAC7.html)
JP2012525358A5 (cg-RX-API-DMAC7.html)